Decrease of TGF-β1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer's disease

Experimental Gerontology

Volumn 37, Issue 6, 2002, Pages 813-821

  De Servi, B ^a   La Porta, C A M ^a   Bontempelli, M ^b   Comolli, R ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

2 Macroglobulin; Alzheimer's disease; Leukocytes; Nitric oxide synthase; Plasma; Transforming growth factor 1

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; NITRIC OXIDE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA1; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; BRAIN LEVEL; CELL ISOLATION; CELL LEVEL; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE MARKER; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; HUMAN CELL; ISOLATION PROCEDURE; LEUKOCYTE; MALE; MEDIATOR; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; SEX; BLOOD; ENZYMOLOGY;

ALPHA-MACROGLOBULINS; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; HUMANS; LEUKOCYTES; NITRIC OXIDE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0036591426     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0531-5565(02)00018-9     Document Type: Article

References (51)

1. Inflammation and Alzheimer's disease
2. Cytokine and acute neurodegeneration
3. Association between an a2 macroglobulin DNA polymorphism and late-onset Alzheimer's disease
4. Alpha-2 macroglobulin is genetically associated with Alzheimer disease
5. No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression
6. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease
7. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum
8. Isolation of nitric oxide sinthase, a calmodulin-requiring enzyme
9. Nitric oxide synthases: Targets for therapeutic strategies in neurological diseases
10. Serum cytokine levels in patients with Alzheimer's disease
11. Reversible inhibition of cytocrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain by nitric oxide. Implications for neurodegenerative diseases
12. A2-macroglobulin and the risk of Alzheimer's disease
13. Nitric oxide synthase activity is elevated in brain microvessels in Alzheimer's disease
14. Altered expression of transforming growth factor-beta in Alzheimer's disease
15. Identical or overlapping sequences in the primary structure of human a2-macroglobulin are responsible for the binding of nerve growth factor-β, platelet-derived growth factor-BB, and transforming growth factor-β
16. Nitric oxide synthases: Properties and catalytic mechanism
17. Relative sparing of nitric oxide synthase-containing neurons in the hippocampal formation in Alzheimer's disease
18. Brain cytocrome oxidase in Alzheimer's disease
19. A2-macroglobulin in late-onset Alzheimer's disease
20. Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients
21. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
22. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: Interleukin-1β, Interleukin-6, Interleukin-1 receptor antagonist, Tumor necrosis factor-a, the soluble tumor necrosis factor receptors I and II, and a1-antichymotrypsin
23. Age dependent modulation of PKC isoforms and NOS activity and expression in rat cortex, striatum and hippocampus
24. Genetic association of an a2-macroglobulin (Val1000ile) polymorphism and Alzheimer's disease
25. Protein measurement with the Folin Phenol Reagent
26. Alpha 2-macroglobulin functions as a cytokine carrier to induce nitric oxide synthesis and cause nitric oxide-dependent cytotoxicity in the RAW 264.7 macrophage cell line
27. Cellular signaling roles of TGF-β, TNF-a and βAPP in brain injury responses and Alzheimer's disease
28. Nitric oxide takes center stage with newly defined roles
29. The importance of inflammatory mechanisms in Alzheimer disease
30. Cerebrospinal fluid nitrite/nitrate levels in neurological diseases
31. Nitric oxide physiology, pathophysiology, and pharmacology
32. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease
33. Cerebrospinal fluid nitrate levels in patients with Alzheimer's disease
34. Latent transforming growth factor-β in serum
35. Electron transport chain defects in Alzheimer disease brain
36. Beta-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex
37. TGF-β in the central nervous system: Potential roles in ischemic injury and neurodegenerative diseases
38. Molecular pathogenesis of sporadic and familial forms of Alzheimer's disease
39. The pattern of NADPH-diaphorase staining, a marker of nitric oxide synthase activity, is altered in the perforant pathway terminal zone in Alzheimer's disease
40. Inflammation and Alzheimer's disease pathogenesis
41. A2-macroglobulin polymorphism is not associated with AD or AD-type neurophatology in the Japanese
42. A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders
43. Differential expression of transforming growth factor-beta isoforms in human prion diseases
44. Neurodegenerative disorders: The role of peroxynitrite
45. Electrophoretic transfer of protein from polyacrylamide gels to nitrocellulose sheets
46. A-2-Macroglobulin expression in neuritic-type plaques in patients with Alzheimer's disease
47. Control of nitric oxide production by transforming growth factor-β1: Mechanistic insights and potential relevance to human disease
48. Spontaneously increased production of nitric oxide synthase in vivo in the transforming growth factor-β1 null mouse
49. Murine a-macroglobulins demonstrate divergent activities as neutralizers of transforming growth factor-β and as inducers of nitric oxide synthesis
50. Localization of the binding site for transforming growth factor-β in human a2-macroglobulin to a 20 kDa peptide that also contains the bait region
51. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice